DMKC Advisory Services LLC Has $2.83 Million Stock Position in Pfizer Inc. $PFE

DMKC Advisory Services LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 21.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 117,624 shares of the biopharmaceutical company’s stock after buying an additional 20,584 shares during the quarter. DMKC Advisory Services LLC’s holdings in Pfizer were worth $2,832,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vermillion Wealth Management Inc. lifted its stake in shares of Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 382 shares during the period. Triad Wealth Partners LLC increased its stake in Pfizer by 1.9% in the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after buying an additional 386 shares during the last quarter. Eagle Capital Management LLC boosted its position in Pfizer by 0.3% during the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after purchasing an additional 390 shares during the last quarter. ETF Store Inc. lifted its stake in Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after acquiring an additional 396 shares during the last quarter. Finally, Delta Financial Advisors LLC raised its stake in Pfizer by 1.6% in the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after buying an additional 398 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. Citigroup increased their target price on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. Guggenheim decreased their price target on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Monday, July 13th. Bank of America cut their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. CICC Research initiated coverage on Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price for the company. Finally, JPMorgan Chase & Co. cut their target price on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $28.50.

Pfizer Trading Up 1.4%

Shares of NYSE:PFE opened at $25.76 on Thursday. The company has a market cap of $146.84 billion, a P/E ratio of 33.90 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The stock’s fifty day moving average price is $25.01 and its 200-day moving average price is $26.16. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.38% and a net margin of 6.80%.The firm’s revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q2 results exceeded expectations. Pfizer reported adjusted earnings of $0.77 per share versus the $0.68 analyst consensus and revenue of $15.03 billion versus $14.40 billion expected. Revenue rose 2.6% year over year, led in part by strong demand for the blood thinner Eliquis. Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
• Positive Sentiment: Pfizer raised its 2026 revenue outlook. The company increased its revenue range to $60.5 billion-$62.5 billion from $59.5 billion-$62.5 billion, lifting the midpoint by $500 million while reaffirming adjusted EPS guidance of $2.80-$3.00. Growth from oncology, launched products and acquired medicines is helping offset weaker COVID sales. Pfizer tops quarterly estimates and hikes revenue guidance
• Positive Sentiment: Additional savings could support profitability. Pfizer targeted $2.5 billion in further cost reductions, expected to be implemented by 2029, as it works to improve efficiency and reduce reliance on older products. Pfizer targets additional cost cuts
• Positive Sentiment: Pipeline news adds potential upside. Pfizer reported positive Phase 3 data for Litfulo in vitiligo, while investors are also watching an obesity-treatment candidate and expanded oncology research for future growth catalysts. Pfizer reports positive Phase 3 Litfulo data
• Neutral Sentiment: Healthcare deal speculation and Pfizer’s acquisition activity remain additional factors investors are monitoring, but no transaction was confirmed in the reported coverage.
• Negative Sentiment: COVID vaccine and treatment demand continues to decline, and Pfizer still faces patent expirations and questions about whether its pipeline can replace lost blockbuster revenue. The quarter also included a reported net loss, while EPS guidance remains slightly below the analyst consensus.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.